PharmaCorp Announces C$15 Million Bought Deal Public Offering

Executive Summary

• PharmaCorp Rx Inc. announced a bought‑deal private placement of 35.7 million units at C$0.42 per unit, targeting gross proceeds of approximately C$15.0 million.
• Each unit consists of one common share and half of a common‑share purchase warrant (full warrant exercisable at C$0.50 for 24 months).
• Net proceeds are earmarked for future pharmacy acquisition opportunities and general working capital; the closing is expected around November 12, 2025, subject to regulatory approvals.

Key Details

• Units Offered: 35.7 million units (each = 1 common share + ½ warrant)
• Offering Price: C$0.42 per unit
• Gross Proceeds: Approximately C$15.0 million
• Underwriters: Syndicate co‑led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd. (bought‑deal basis)
• Warrant Terms: Whole warrant gives right to purchase one common share at C$0.50; warrants exercisable for 24 months from the Closing Date.
• Over‑Allotment Option: Up to an additional 15 % of units may be purchased by the underwriters within 30 days post‑closing, at the same price, for market stabilization.
• Closing Date: Expected on or about November 12, 2025, pending TSX Venture Exchange and other regulatory approvals.
• Use of Proceeds: Primarily to fund future pharmacy acquisitions and for general working capital requirements.
• Prospectus Documentation: Units will be offered via a prospectus supplement attached to the Company’s short‑form base shelf prospectus dated October 14, 2025; filings available on SEDAR+.

Notable Quotes

(No executive quotes were included in the release.)